Overview

Study of Tazemetostat With Enzalutamide or Abiraterone/Prednisone in Subjects With Castration Resistant Prostate Cancer Who Have Not Received Chemotherapy

Status:
Recruiting
Trial end date:
2022-08-01
Target enrollment:
Participant gender:
Summary
A phase 1b/2 study to examine taz in combination with enz or abi/pred in patients with metastic castration resistant prostate cancer
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Epizyme, Inc.
Treatments:
Prednisone